Is Ponatinib on the market?

Ponatinib (Ponatinib) has been approved by the U.S. Food and Drug Administration (FDA) for sale under the trade name Iclusig and has also been approved by the European Medicines Agency (EMA). Ponatinibis a new typeBcr-Abl tyrosine kinase inhibitor, which is particularly effective against T315I mutation and is used to treat chronic myelogenous leukemia (CML).

Ponatinib is indicated for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myeloid leukemia (CML) who are resistant to or intolerant to prior tyrosine kinase inhibitor therapy, or adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) who are resistant to or intolerant to prior tyrosine kinase inhibitor therapy. Common non-hematological adverse reactions (≥20%) are hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation, joint pain, nausea, and pyrexia. Hematological adverse reactions include thrombocytopenia, anemia, neutropenia, lymphopenia, and leukopenia.

The original drug of Ponatinib has not yet been launched in China, so it is not included in the medical insurance. Domestic patients in need may only purchase it through overseas channels. The Hong Kong original version of Ponatinib specificationsThe price of 45mg*30 tablets per box may be around 40,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also generic ponatinib drugs produced in other countries, which are relatively cheap. The price of 45mg*30 tablets per box produced by Everest Pharmaceutical Factory in Bangladesh may be around 4,000 yuan (the price may fluctuate due to the exchange rate), and its drug ingredients are basically the same as those of the original drug.